AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
Zacks
More News
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
Zacks
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Zacks
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Zacks
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.
Zacks
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks
Key PointsThanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound...
Nasdaq News: Markets
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
Zacks
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
read more...
Benzinga
TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU
Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).
Zacks
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.